Opendata, web and dolomites

Balanseat Phase-1

THE ONLY WALKING REHABILITATION DEVICE THAT FITS THE CAPABILITIES OF THE FRAIL ELDERLY & NEUROLOGICAL IMPAIRED

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "Balanseat Phase-1" data sheet

The following table provides information about the project.

Coordinator
MOPAIR TECHNOLOGIES LTD. 

Organization address
address: EIN GEDI 7
city: HADERA
postcode: 3831003
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website https://balanseat.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MOPAIR TECHNOLOGIES LTD. IL (HADERA) coordinator 50˙000.00

Map

 Project objective

One of the common gait impairments among the elderly is reduction in trunk and pelvic rotation, which leads to increased risk of falls and loss of independence. However, common rehabilitation devices focus mainly on leg exercise and ignore the effect of trunk and pelvic rotation on walking. Moreover, the frail senior, as well as the neurologically impaired patient who suffer from advanced gait impairments lack the strength to cope with leg exercises that are performed while walking. Therefore, this population deteriorates, becomes home-bound and falls. Mopair's device, Balanseat, applies thoraco-pelvic rotation and thighs extension to a seated user. Thus, the frail senior, as well as the neurologically impaired is expected to find this treatment the only training modality they can cope with. Moreover, Balanseat approach is assumed to provide the comprehensive treatment that exceeds beyond the existing leg-exercise approach. A case series with 19 frail residents from an assisted living home demonstrated marked improvement in the functional-parameters that are correlated to fall-risk and level of ambulation. Clinical indications from neurologically impaired patients, as well as from two home-users who use Balanseat for more than 6 months, are similar. In parallel to the commercialization of this fundamental device, Mopair is planning to pursue a sensor-embedded device that senses the user's capabilities and progression. Sensors' outcomes, that enable personalization of treatment programs, will lead Mopair to fulfil its long-term vision of developing an autonomous therapist for the frail elderly and neurologically impaired – maybe, the only modality that can survive the challenge of the growing of Balanseat target population together with the shrinking of the healthcare resources. Balanseat is a revolutionary solution for walking rehabilitation, reducing risk of falls and improving ambulation for older adults and neurological impaired.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BALANSEAT PHASE-1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BALANSEAT PHASE-1" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

NAAS (2019)

NaaS - Newsroom as a service

Read More  

HAC (2019)

ADVANCED TREATMENT OF CONTAMINATED SOIL

Read More  

SA-VOIR (2019)

Assessing the feasibility of MT-011, a first-in-class drug to treat glaucoma and other neurodegenerative diseases via a breakthrough mechanism-of-action

Read More